Amphotericin B Liposomal Inj 50 mg vial: Hospital supply issue
Boucher & Muir (BNM), the supplier, has placed a quality hold on their stock (and wholesalers' stock) of Amphotericin Liposomal SUN 50 mg vial (Pharmacode 2714264).
Update 21 October 2026 | Alternative sourced
An alternative, AmBisome, is arriving 22 October 2026. The supplier is working to release stock as soon as possible, most likely stock will be at wholesalers for hospitals to order from the week beginning 26 October 2026, which is Labour Day.
Affected product
Boucher & Muir (BNM), the supplier of this product, has placed a quality hold on all stock on hand, including stock held by wholesalers. This hold has immediate effect. BNM advises that this is a precautionary measure while a potential sterility issue is investigated.
Chemical: Amphotericin B
- Presentation: Inj (liposomal) 50 mg vial
- Brand: Amphotericin Liposomal SUN
- Pharmacode: 2714264
- Price: $125.00
- Measure / Qty: per 1
Actions for hospitals
At this stage, hospitals can continue to use any stock that they hold.
We recommend that hospitals review current stock holdings and closely manage usage until Ambisome is available.
Alternative product
An alternative has been sourced, AmBisome, which was the previously funded product. Stock should be available from wholesalers during the week beginning 26 October 2026.
- Brand name: AmBisome
- Pharmacode: 2229323
- Price: $3,541.43
- Measure/Qty: 10 vials per pack
Expected resolution
Based on current information, BNM anticipates that the quality hold will be lifted by the end of November 2026.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)